The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial
Open accessAbstract
Background: Long acting insulin detemir administered intranasally for three weeks enhanced memory for adults with Alzheimer’s disease dementia (AD) or amnestic mild cognitive impairment (MCI). The investigation of longer-term administration is necessary to determine whether benefits persist, whether they are similar to benefits provided by regular insulin, and whether either form of insulin therapy affects AD biomarkers. Objective: The present study aimed to determine whether four months of treatment with intranasal insulin detemir or regular insulin improves cognition, daily functioning, and AD biomarkers for adults with MCI or AD. Methods: This randomized, double-blind, placebo-controlled trial included an intent-to-treat sample consisting of 36 adults diagnosed with MCI or mild to moderate AD. Participants received placebo ( n = 12), 40 IU of insulin detemir ( n = 12), or 40 IU of regular insulin ( n = 12) daily for four months, administered with a nasal delivery device. A cognitive battery was administered at baseline and after two and four months of treatment. MRI was administered for all participants and lumbar puncture for a subset ( n = 20) at baseline and four months. The primary outcome was change from baseline to four months on a memory composite (sum of Z scores for delayed list and story recall). Secondary outcomes included: global cognition (Alzheimer’s Disease Assessment Scale-Cognition), daily functioning (Dementia Severity Rating Scale), MRI volume changes in AD-related regions of interest, and cerebrospinal fluid AD markers. Results: The regular insulin treated group had better memory after two and four months compared with placebo ( p < 0.03). No significant effects were observed for the detemir-assigned group compared with the placebo group, or for daily functioning for either group. Regular insulin treatment was associated with preserved volume on MRI. Regular insulin treatment was also associated with reduction in the tau-P181/Aβ 42 ratio. Conclusion: Future research is warranted to examine the mechanistic basis of treatment differences, and to further assess the efficacy and safety of intranasal insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A device for IN delivery that had been successfully used in previous studies 75,76,107 proved unreliable in the first 49 participants because of malfunctions of a newly added electronic timer.”
From Intranasal insulin (2021) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Voxel-Based Morphometry—The Methods
Ashburner, J., & Friston, K. J. (2000) · NeuroImage · doi:10.1006/nimg.2000.0582 · Cited by 8,676
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Self-citationIntranasal insulin improves cognition and modulates β-amyloid in early AD
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Breitner, J. C. S., DeGroodt, W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000265401.62434.36 · Cited by 830
Self-citationRoberts, R. O., Geda, Y. E., Knopman, D. S., Cha, R. H., Pankratz, V. S., Boeve, B. F., Ivnik, R. J., Tangalos, E. G., Petersen, R. C., & Rocca, W. A. (2008) · Neuroepidemiology · doi:10.1159/000115751 · Cited by 797
De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657 · cited 1×
“phorylation in preclinical models [4].”
Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–335 of 335
TARGETABLE MULTI-DRUG NANOPARTICLES FOR TREATMENT OF GLIOBLASTOMA WITH NEUROIMAGING ASSESSMENT
Smiley, S. B. (2020) · Purdue e-Pubs (Purdue University System) · doi:10.25394/pgs.12221780.v1
Rosenzweig, S. A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732579862.793572336
Bayunova, L. V., Захарова, И. О., Илясов, И., Avrova, D. K., Fokina, E. A., & Avrova, N. F. (2022) · Международная научно-практическая конференция «Актуальные проблемы науки и образования в условиях современных вызовов» · doi:10.33184/snfipa-2022-10-19.3
Progress on Factors Influencing Cognitive Dysfunction in Patients with Type 2 Diabetes
刘, 敏. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.132351
Intranasal insulin therapy in the treatment of alzheimer’s disease – A narrative review
Nene, A., & Santoni, J. R. (2023) · IP Indian Journal of Anatomy and Surgery of Head Neck and Brain · doi:10.18231/j.ijashnb.2023.006
Moore, A. K., & Ritchie, M. D. (2023) · medRxiv · doi:10.1101/2023.11.06.23297993
Zakharova, I. O., Bayunova, L. V., Derkach, K. V., Shpakov, A. O., & Avrova, N. F. (2023) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093023060042
Insulin and neurodegenerative diseases
Ferris, H. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00012-7
Combination therapies delay cognitive decline over 10 years in Alzheimer’s NACC participantsPreprint
Shang, Y., Torrandell‐Haro, G., Vitali, F., & Brinton, R. D. (2024) · medRxiv · doi:10.1101/2024.01.31.24301055
Zakharova, I. O., Bayunova, L. V., Derkach, K. V., Shpakov, A. O., & Avrova, N. F. (2023) · Журнал эволюционной биохимии и физиологии · doi:10.31857/s0044452923060104
Zakharova, I. O., Zorina, I. I., Bayunova, L. V., Shpakov, A. O., & Avrova, N. F. (2023) · Журнал эволюционной биохимии и физиологии · doi:10.31857/s0044452923010096
Fokina, E. A., Zakharova, I. O., Bayunova, L. V., Avrova, D. K., Ilyasov, I. O., & Avrova, N. F. (2023) · Журнал эволюционной биохимии и физиологии · doi:10.31857/s0044452923010047
Andrade, L. J. D. O., de Oliveira, G. C. M., & de Oliveira, L. M. (2024) · medRxiv · doi:10.1101/2024.06.21.24309323
Altered Glucose Homeostasis in Neurological Disorders
Shrivastava, N. K., & Shakarad, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-4288-2_5
Zakharova, I. O., Bayunova, L. V., Avrova, D. K., & Avrova, N. F. (2024) · Журнал эволюционной биохимии и физиологии · doi:10.31857/s0044452924010053
Peptides, Proteins and Antibodies
Gennaro, S. I. D., & Lalatsa, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-59478-6_19
Protein and peptide delivery through respiratory pathway
Tandel, H., Florence, K., Upadhyay, M., & Chougule, M. B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27416-9.00009-5
An overview of intranasal drug delivery systems for Alzheimer’s disease
Unnissa, Z., Unissa, M., Hussain, M. M., & Ali, S. S. (2025) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20253380
Insulin use in diabetes association with cognitive impairment and dementia incidence
Hajihosseini, S., Kurd, D. M., Nouroozi, F., Haghighi, S., Dini, N., Ghobadi, Y., Tehrani, N., Shahrokhi, M., Belbasi, M., Alizadeh, H., et al. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-01042-7
Metabolic connections between Alzheimer's disease and diabetes
Adhikary, K., Ganguly, K., Chowdhury, S. R., & Banerjee, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00024-4
Wang, H., & Yao, Z. (2025) · Neuropharmacology and Therapy · doi:10.15212/npt-2025-0026
Tiburcio, M. A., SILVA, B. Z., Garcia, M. L. D. C., Pereira, L. M. B., Grigoli, M. M., Cominetti, M. R., & Carlos, R. M. (2026) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2026.113225
Alzheimer’s disease: diabetes of the brain
Moreira, P. I., Cardoso, S., & Perry, G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33841-0.00030-0
Diabetes, Protein Misfolding, and Heat Stress: Molecular Insights and Translational Perspectives
Abreu, M. M., Spitz, V. H., & Smadja, D. M. (2026) · TH Open · doi:10.1055/a-2790-5251
Raffaelli, L., Palladini, M., Paolini, M., Poletti, S., Lorenzi, C., Decorato, R., Carminati, M., Colombo, C., Zanardi, R., Benedetti, F., et al. (2026) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2026.02.003
Connecting the Dots: Neurobiological Interplay Between Type 2 Diabetes and Alzheimer’s Disease
Foncea-Bitrán, A., Barros-Osorio, C., Arriaza, F., Ramírez-López, C., Ruíz, L. M., Barreto, M., Ortíz, F. C., Cornejo, F., & Gómez, G. I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073225
Frison, É. (2019) · theses.fr (ABES) · doi:10.70675/a527bd03zb814z44e5z8848z942b662a0847
Delangre, E. (2021) · theses.fr (ABES) · doi:10.70675/622d48edz59dcz427ez85c9z9da5f8129e84
Alkhoujah, S. M., Zenati, R. A., Ahmed, M., Jaber, S. A., Abuhelwa, A. Y., Aleidi, S. M., Farheen, S., Albohy, A., Khabour, O. F., Masadeh, M. M., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05686-y
Ferris, H. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00010-x
Safety and tolerability of intranasal insulin in Parkinson’s disease
Johnson, J. C., Kashyap, B., Gustafson, S. K., O’Brien, M., Frey, W. H., Svitak, A. L., & Hanson, L. R. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1875165
Nose-to-Brain Inorganic Nanosystems for Alzheimer’s Disease Theranostics
González-Pizarro, C., Vitta, Y., & Kogan, M. J. (2026) · Journal of Pharmaceutical and BioTech Industry · doi:10.3390/jpbi3040024
Ayan, E. B., Palermo, F., Cavioli, G., Bostan, S., Doğan, B. Z., Kılıç, K., Kaplan, A. A., Bukreeva, I., Massimi, L., Longo, E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.10.758244
Metadata
- Authors
- Craft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., Jung, Y., Maldjian, J., Whitlow, C., & Friedman, S.
- Affiliations
- Wake Forest University Health Sciences (US)
- Alkermes (United States) (US)
- University of Washington (US)
- Stanford Medicine (US)
- The University of Texas Southwestern Medical Center (US)
- Seattle Children's Hospital (US)
- Corresponding author
- Craft, Suzanne
- ORCID
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-03-29
- Volume
- 57
- Issue
- 4
- Pages
- 1325-1334
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5409050
- OpenAlex
- W2600568015
- Cited by
- 335
- References
- 33
- Citations by year
- 2026: 13 · 2025: 40 · 2024: 25 · 2023: 47 · 2022: 32 · 2021: 46 · 2020: 49 · 2019: 46 · 2018: 29 · 2017: 8
- FWCI
- 26.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Alzheimer's Association (ZEN-10-173646)
- National Institute on Aging (P30AG049638)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- intranasal insulin, insulin detemir
- MeSH terms
- Activities of Daily Living, Aged, Alzheimer Disease, Brain, Cognition, Double-Blind Method, Female, Humans, Magnetic Resonance Imaging, Male, Organ Size, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Outcome, Nootropic Agents, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
